Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia ... in patients aged 12 and older and is the first drug in the anti-TFPI class to be approved in ...

The healthcare industry thrives due to novel drug pipeline discoveries, AI integration to streamline processes and ...

Pfizer has received approval from the US FDA for its rheumatoid arthritis (RA) drug, Xeljanz, which is the first approved RA treatment in a new class of medicines known as Janus kinase inhibitors ...

NEW YORK, October 11, 2024--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI ... of age and older with hemophilia A (congenital ...

The Food and Drug Administration (FDA) of the United States Friday issued an emergency clearance for the use of the Pfizer / BioNTech ... After the FDA's approval, the Centers for Disease Control ...

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the companies'... By Patrick Wingrove ...

with hemophilia A or… The U.S. Food and Drug Administration (FDA) has approved Pfizer’s marstacimab under the brand name Hympavzi for use as a routine prophylaxis to prevent or reduce the frequency of ...

Investors looking to tap into this expanding sector may find good opportunities in established healthcare leaders, Pfizer Inc ...

The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...

The U.S. Food and Drug Administration has approved PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq) for the ...

Applied Therapeutics said on Monday it received a warning letter limited to a trial studying its genetic disease drug, after ...